In the inaugural episode, we explore the origins of BioLineRx and its transformation from a biotech incubator to a fully-fledged biotech company. Joined by Phil Serlin, CEO of BioLineRx, we uncover the company's early days, its broad pipeline spanning various therapeutic areas, and the strategic decision-making process that led to its evolution. From strategic evaluations to pivoting towards oncology and hematology, this episode highlights the importance of persistence and strategic adaptability in the biotech industry.